-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] The pharmaceutical industry has attracted much attention from institutio.
In the past week, many pharmaceutical companies have received institutional buy ratin.
For example, Sinolink Securities gave Borui Pharmaceuticals a buy rating, and Citigroup maintained a buy rating for Zaiyi Pharmaceutic.
On August 9, Sinolink Securities conducted research on Borui Medicine and released the research report "Proficient in Scarce and Difficult Synthetic Drugs, Deploying High-end Preparation Capacit.
This report gives a buy rating to Borui Medicine, and the current share price is 29 yu.
It believes that Borui Pharmaceutical's future preparation sales will enter a period of rapid volume increase with the approval of new varieties and centralized procurement, and the API business has formed a relatively stable cooperative relationship with custome.
It is expected that Borui Pharmaceutical will achieve revenue of 257 billion yuan/515 billion yuan/853 billion yuan in 2022/23/24; considering that the API will be subject to price pressure after the product enters the centralized procurement, the gross profit margin in 2022/23/24 is expected to be 579 %/548%/51
It is reported that Borui Medicine combines imitation and innovation, and innovative polymer conjugated drugs enter the clinic, opening the long-term ceili.
Based on the drug conjugate platform development, different from traditional polymer conjugated drugs, the company's polymer conjugated drugs are target.
The candidate drug BGC0228 can enrich the drug in the diseased tissue while reducing toxic and side effects; BGM0504 is GLP-1 /GIP dual agonists, for glycemic control, weight loss and NASH, have shown better efficacy potential than approved produc.
In the past 90 days, a total of 3 institutions of Borui Pharmaceutical have given ratings and 3 have increased their holdin.
On August 9, Citigroup maintained a buy rating on Zai Lab, with the latest target price of $19
According to the data, Zai Lab is an innovative, R&D-based and commercial-stage biopharmaceutical company, focusing on the discovery, licensing, development and commercialization of differentiated innovative therapies that can address the huge medical demand gap in China and the global market therapy, including oncology, anti-infective and autoimmune diseas.
By effectively executing the company's plan and closely following the company's strategy, the company has created a comprehensive platform to deliver new, licensed and in-house developed therapies to patients around the wor.
The agency believes that Zai Lab is one of the earliest biopharmaceutical companies in China to expand in scale, which enables the company to further take advantage of new global innovations and business opportuniti.
According to the data, Zai Lab's 2022 interim results, total revenue is about 99 million US dollars, a year-on-year increase of 638%; net loss is about 220 million US dollars, a year-on-year decrease of about 43
In the past 90 days, a total of 5 investment banks of Zai Lab gave buy ratings, and the average target price in the past 90 days was 66On August 8, Capital Securities issued a research report saying that it gave Furui a buy rati.
The reasons for the rating mainly include: 1) The global NASH innovative drugs have entered a breakthrough period, and FibroScan has broad prospects; 2) The sales model of Fufang Biejia Ruanggan Tablets has been successfully switched, and the profitability of the pharmaceutical sector is expected to gradually impro.
On August 4, Cinda Securities issued a research report saying that it gave Zhenbao Island a buy rati.
The reasons for the rating mainly include: 1) frequent policies to promote the innovation and development of pharmaceuticals; 2) the field of traditional Chinese medicine: the secondary development promotes product quality and price increases, and the upstream and downstream are integrated to build a platform for the whole industry chain; 3) the fields of chemical and biological drugs: increase Thickened the drug pipeline, and participated in the participation of Tris in the field of biological dru.
In addition, Nomura recently released a research report saying that it maintains the "buy" rating of WuXi Biologi.
It is expected that the company's revenue will increase by 62% year-on-year in the first half of this year, and its net profit will increase by 37% year-on-ye.
At the same time, the 2022/23 fiscal year revenue forecast is increased by 3%/4%, and the profit forecast is increased by 10%/6% to reflect the stronger growth momentum, and the target price is raised from HK$975 to HK$97Capital Securities recently gave Kangchen Pharmaceutical a buy rating, and the current share price is 214 yu.
Capital Securities predicts that the operating income of Kangchen Pharmaceutical in 2022-2024 will be 865, 937 and 053 billion yuan respectively, with a year-on-year growth rate of 9%, 3% and 13% respectively; the net profit attributable to the parent will be 49, 67 and 185 million yuan respective.
, the year-on-year growth rates were 9%, 19% and 17%, respective.
Based on the closing price on August 2, the corresponding PEs were 20, 17 and 19 times, respective.
Taking into account the steady progress of the company's R&D pipeline, maintain a "buy" rati.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
In the past week, many pharmaceutical companies have received institutional buy ratin.
For example, Sinolink Securities gave Borui Pharmaceuticals a buy rating, and Citigroup maintained a buy rating for Zaiyi Pharmaceutic.
On August 9, Sinolink Securities conducted research on Borui Medicine and released the research report "Proficient in Scarce and Difficult Synthetic Drugs, Deploying High-end Preparation Capacit.
This report gives a buy rating to Borui Medicine, and the current share price is 29 yu.
It believes that Borui Pharmaceutical's future preparation sales will enter a period of rapid volume increase with the approval of new varieties and centralized procurement, and the API business has formed a relatively stable cooperative relationship with custome.
It is expected that Borui Pharmaceutical will achieve revenue of 257 billion yuan/515 billion yuan/853 billion yuan in 2022/23/24; considering that the API will be subject to price pressure after the product enters the centralized procurement, the gross profit margin in 2022/23/24 is expected to be 579 %/548%/51
It is reported that Borui Medicine combines imitation and innovation, and innovative polymer conjugated drugs enter the clinic, opening the long-term ceili.
Based on the drug conjugate platform development, different from traditional polymer conjugated drugs, the company's polymer conjugated drugs are target.
The candidate drug BGC0228 can enrich the drug in the diseased tissue while reducing toxic and side effects; BGM0504 is GLP-1 /GIP dual agonists, for glycemic control, weight loss and NASH, have shown better efficacy potential than approved produc.
In the past 90 days, a total of 3 institutions of Borui Pharmaceutical have given ratings and 3 have increased their holdin.
On August 9, Citigroup maintained a buy rating on Zai Lab, with the latest target price of $19
According to the data, Zai Lab is an innovative, R&D-based and commercial-stage biopharmaceutical company, focusing on the discovery, licensing, development and commercialization of differentiated innovative therapies that can address the huge medical demand gap in China and the global market therapy, including oncology, anti-infective and autoimmune diseas.
By effectively executing the company's plan and closely following the company's strategy, the company has created a comprehensive platform to deliver new, licensed and in-house developed therapies to patients around the wor.
The agency believes that Zai Lab is one of the earliest biopharmaceutical companies in China to expand in scale, which enables the company to further take advantage of new global innovations and business opportuniti.
According to the data, Zai Lab's 2022 interim results, total revenue is about 99 million US dollars, a year-on-year increase of 638%; net loss is about 220 million US dollars, a year-on-year decrease of about 43
In the past 90 days, a total of 5 investment banks of Zai Lab gave buy ratings, and the average target price in the past 90 days was 66On August 8, Capital Securities issued a research report saying that it gave Furui a buy rati.
The reasons for the rating mainly include: 1) The global NASH innovative drugs have entered a breakthrough period, and FibroScan has broad prospects; 2) The sales model of Fufang Biejia Ruanggan Tablets has been successfully switched, and the profitability of the pharmaceutical sector is expected to gradually impro.
On August 4, Cinda Securities issued a research report saying that it gave Zhenbao Island a buy rati.
The reasons for the rating mainly include: 1) frequent policies to promote the innovation and development of pharmaceuticals; 2) the field of traditional Chinese medicine: the secondary development promotes product quality and price increases, and the upstream and downstream are integrated to build a platform for the whole industry chain; 3) the fields of chemical and biological drugs: increase Thickened the drug pipeline, and participated in the participation of Tris in the field of biological dru.
In addition, Nomura recently released a research report saying that it maintains the "buy" rating of WuXi Biologi.
It is expected that the company's revenue will increase by 62% year-on-year in the first half of this year, and its net profit will increase by 37% year-on-ye.
At the same time, the 2022/23 fiscal year revenue forecast is increased by 3%/4%, and the profit forecast is increased by 10%/6% to reflect the stronger growth momentum, and the target price is raised from HK$975 to HK$97Capital Securities recently gave Kangchen Pharmaceutical a buy rating, and the current share price is 214 yu.
Capital Securities predicts that the operating income of Kangchen Pharmaceutical in 2022-2024 will be 865, 937 and 053 billion yuan respectively, with a year-on-year growth rate of 9%, 3% and 13% respectively; the net profit attributable to the parent will be 49, 67 and 185 million yuan respective.
, the year-on-year growth rates were 9%, 19% and 17%, respective.
Based on the closing price on August 2, the corresponding PEs were 20, 17 and 19 times, respective.
Taking into account the steady progress of the company's R&D pipeline, maintain a "buy" rati.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
